capmatinib + tepotinib

Capmatinib and tepotinib are potent, highly selective MET (mesenchymal-epithelial transition) tyrosine kinase inhibitors approved for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. Both drugs demonstrate robust response in NSCLC patients with these mutations. Tepotinib has an IC50 of 4 nM in a cell-free assay, while capmatinib has an IC50 of 0.13 nM. They have different metabolic pathways - capmatinib is metabolized mainly by CYP3A, which is not involved in the metabolism of tepotinib. Both drugs commonly cause peripheral edema as a side effect, though the severity may differ between the two medications. In some cases, patients who experience intolerable edema with one MET inhibitor may be able to continue treatment by switching to the other.